It is also approved to reduce the risk of major cardiovascular events, such as heart attack, stroke, and cardiovascular death, in people with Type 2 diabetes and heart disease
In November 2023, tirzepatide for chronic weight management was approved as Zepbound, with SURMOUNT trial data showing mean weight loss of roughly 21% at the 15 mg dose over 72 weeks
We appreciate the support of Amanda Namchuk, Travis Hodges, Bonnie Lee, and Natascha Diekow, who contributed to the experiment endpoints and tissue collections
However, discussion of these uses is beyond the scope of this article
Its easy, non-invasive, and fits seamlessly into most routines
Podsumowanie Prawidowe funkcjonowanie ukadu krenia jest niezbdne dla prawidowego funkcjonowania organizmu ale take ycia